Emerald Advisers »

Apellis Pharmaceuticals shares owned by Emerald Advisers

Quarter-by-quarter ownership of Apellis Pharmaceuticals (APLS) shares owned by Emerald Advisers from 13F filings

Historical chart of Emerald Advisers investment in Apellis Pharmaceuticals

Tip: Access up to 7 years of quarterly data

All positions including Apellis Pharmaceuticals held by Emerald Advisers consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Apellis Pharmaceuticals by Emerald Advisers

Quarter filed Position value Share count Share price at filing
2023-12-31 $254k 4.2k 59.86

More positions owned by Emerald Advisers

ImmunoGen
ACADIA Pharmaceuticals (ACAD)
Freshpet (FRPT)
Carpenter Technology Corporation (CRS)
Super Micro Computer (SMCI)
Churchill Downs (CHDN)
Varonis Sys (VRNS)
Blueprint Medicines (BPMC)
Transmedics Group (TMDX)
Ftai Aviation (FTAI)
Tenable Hldgs (TENB)
Shift4 Payments Cl A Ord (FOUR)
Kratos Defense & Security Solutions (KTOS)
Chart Industries (GTLS)
Nv5 Holding (NVEE)

View all positions for Emerald Advisers

Top funds holding Apellis Pharmaceuticals

Wellington Management Company
EcoR1 Capital
venBio Select Advisor
Vanguard Group
Jennison Associates
Octagon Capital Advisors
Jpmorgan Chase & Co
T. Rowe Price Associates
Assenagon Asset Management
Logos Global Management
Boxer Capital
Artal Group
Citadel Advisors
Caption Management
Norges Bank Investment Management

View all funds holding Apellis Pharmaceuticals